SCHEMBL850447

SCHEMBL850447

CNC(=N)NCCc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 2/20 0.55
ATM Q13315 1/20 0.55
NPC1 O15118 5/20 0.55
RAB9A P51151 5/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
IDO1 P14902 1/20 0.51
CA12 O43570 3/20 0.50
CA2 P00918 3/20 0.50
CA9 Q16790 3/20 0.50
CA1 P00915 2/20 0.50
ALDH1A1 P00352 2/20 0.49
MAPT P10636 2/20 0.49
LMNA P02545 2/20 0.49
HPGD P15428 1/20 0.49
EPHX1 P07099 1/20 0.49
GAA P10253 1/20 0.49
MEN1 O00255 1/20 0.47
ALOX12 P18054 1/20 0.47
MAPK1 P28482 1/20 0.47
HTT P42858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14868317 0.91 NPC1 (0.50) TAAR1ATMNPC1RAB9ASMN1; SMN2
Hydrochloric Acid SCHEMBL17186225 0.90 NPC1 (0.49) TAAR1ATMNPC1RAB9ASMN1; SMN2
SCHEMBL13584139 0.84 NPC1 (0.59) TAAR1ATMNPC1RAB9ASMN1; SMN2
SCHEMBL3926232 0.82 NPC1 (0.57) TAAR1NPC1RAB9ASMN1; SMN2IDO1
Hydrochloric Acid SCHEMBL13585003 0.82 NPC1 (0.57) TAAR1ATMNPC1RAB9ASMN1; SMN2
SCHEMBL14592922 0.81 NPC1 (0.52) TAAR1ATMNPC1RAB9ASMN1; SMN2
SCHEMBL14868320 0.81 KMT2A (0.51) NPC1RAB9ASMN1; SMN2HPGDEPHX1
SCHEMBL3916719 0.81 NPC1 (0.55) TAAR1ATMNPC1RAB9ASMN1; SMN2
SCHEMBL3998822 0.81 NPC1 (0.55) TAAR1ATMNPC1RAB9ASMN1; SMN2
SCHEMBL17887852 0.81 EPHX1 (0.62) TAAR1NPC1RAB9ASMN1; SMN2IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9109048-B2 Inhibition of tumor growth LYTIX BIOPHARMA AS (NO) 2015-08-18 US disclosed
US-20140037657-A1 INHIBITION OF TUMOR GROWTH LYTIX BIOPHARMA AS (NO) 2014-02-06 US disclosed
US-8143211-B2 Bioactive peptides LYTIX BIOPHARMA AS (NO) 2012-03-27 US disclosed
US-20080287346-A1 Bioactive peptides SVENDSEN JOHN SIGURD 2008-11-20 US disclosed
US-7439228-B2 Bioactive peptides LYTIX BIOPHARMA AS (NO) 2008-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287346-A1 Bioactive peptides VIP, NGLY1, IAPP TAAR1 4773/4885ATM 4352/4885NPC1 1179/4885
US-20140037657-A1 INHIBITION OF TUMOR GROWTH STING1, VIP, MIF TAAR1 4500/4885ATM 3935/4885NPC1 2139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.